Full-Time

State Government Affairs Director

Confirmed live in the last 24 hours

Vertex Pharmaceuticals

Vertex Pharmaceuticals

1,001-5,000 employees

Develops medicines for serious diseases

Compensation Overview

$199.5k - $299.2k/yr

+ Bonus + Equity Awards

Senior, Expert

Company Does Not Provide H1B Sponsorship

Pennsylvania, USA + 5 more

More locations: Delaware, USA | Jackson Township, NJ, USA | Kentucky, USA | Ohio, USA | United States

Incumbent must reside in the region (PA, OH, IN, KY, DE, NJ). Field travel required 40-50%.

Category
Legal Consulting
Consulting
Required Skills
Public Policy
Requirements
  • Minimum of seven to ten years current and relevant experience in state government affairs, state government or at a major trade association with significant direct lobbying experience
  • Demonstrated ability to build and sustain relationships with members of the legislature, administration and other government and community leaders
  • Significant knowledge of state legislative and regulatory systems
  • Demonstrated outstanding strategic planning, communication and presentation skills
  • Bachelor’s degree required (advanced degree preferred) in science, law, government or public policy
  • A high level of energy and passion toward patients, science and public health
  • Proven teamwork and collaboration skills, with a demonstrated ability to interact and influence all levels of business
  • Detail-oriented, self-initiating, well-organized and capable of managing multiple projects simultaneously and independently
  • Demonstrated ability to think outside the box and develop innovative solutions
  • Strong understanding of the legal and regulatory environment along with demonstrated integrity on the job
  • A desire to work in the corporate culture of a highly innovative company aimed at redefining health and transforming lives with new medicines.
Responsibilities
  • Developing, coordinating, and leading the company’s state/regional public policy efforts
  • Working collaboratively with communications, patient advocacy, policy, medical affairs, and marketing departments to ensure that state public policy goals are aligned to meet company objectives and most effectively serve the needs of patients
  • Analyzing and monitoring legislation, regulations, and political activity relating to issues that may impact Vertex
  • Drives strategy and creates plans of actions to impact policy change
  • Developing and maintaining high-level relationships with government officials, community leaders, advocacy groups, external organizations, and stakeholders to achieve Vertex goals
  • Collaborating with and facilitating advocacy coalitions for specific public policy goals, including rare disease awareness and Vertex's commercial and pipeline disease area policy issues
  • Leads complex cross-functional initiatives that have impact across the team
  • Developing as necessary written analyses, testimony and background materials in support of Vertex objectives
  • Leveraging pre-existing relationships as well as facilitating partnerships with additional community-based organizations and coalitions to reach public policy and company goals
  • In partnership with cross-functional partners, integrating Vertex’s public relations objectives with the state/regional public policy strategy and identifying additional opportunities to increase rare disease awareness and disease burden awareness, especially around Vertex's commercial and pipeline disease areas
  • Managing contract lobbyists and overseeing compliance with state laws for lobbyist registration, reporting and political contributions
  • Identifying and pursuing additional opportunities to advance our company’s business objectives
  • Fulfilling other duties/projects as assigned
  • Exemplifying Vertex’s core values in fulfilling these job duties
  • Field Travel required 40-50% (Incumbent must reside in the region (PA, OH, IN, KY, DE, NJ))
Desired Qualifications
  • Pharmaceutical or healthcare sector experience strongly preferred
Vertex Pharmaceuticals

Vertex Pharmaceuticals

View

Vertex Pharmaceuticals develops medicines for serious diseases, focusing on conditions like cystic fibrosis. The company conducts extensive research and development to create new drugs, often collaborating with other biotech firms to enhance its therapeutic offerings. One of its notable products is ivacaftor, which has shown effectiveness in treating cystic fibrosis. Vertex differentiates itself from competitors through its commitment to scientific innovation and strategic partnerships that expand its research capabilities. The goal of Vertex Pharmaceuticals is to improve the quality of life for patients with severe and life-threatening conditions by bringing effective treatments to market.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Boston, Massachusetts

Founded

1989

Simplify Jobs

Simplify's Take

What believers are saying

  • Vertex's EU approval expands its cystic fibrosis treatment market.
  • Partnerships with Arbor and Orna enhance Vertex's gene therapy capabilities.
  • Increased focus on personalized medicine aligns with Vertex's patient-centric approach.

What critics are saying

  • Increased competition in cystic fibrosis could impact Vertex's market share.
  • Regulatory changes in the EU may delay Vertex's drug approvals.
  • High R&D costs and potential trial failures could strain Vertex's finances.

What makes Vertex Pharmaceuticals unique

  • Vertex focuses on transformative medicines for serious diseases, like cystic fibrosis.
  • The company invests heavily in R&D and strategic partnerships for drug development.
  • Vertex's innovative cell and gene therapies set it apart in the biotech industry.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Hybrid Work Options

Company News

Buniversity
May 1st, 2025
VERTEX upset Grayhound for spot at BLAST Showdown

VERTEX locked in a first-place finish at Fortress OCE Masters Fall 2022 Finals in Melbourne to qualify for BLAST Premier Fall Showdown.

BioSpace
Apr 14th, 2025
Vertex Researcher, Paul Negulescu Ph.D., Receives the 2025 Canada Gairdner International Award for Pioneering Research and Discovery of Medicines for Cystic Fibrosis

Vertex researcher, Paul Negulescu Ph.D., receives the 2025 Canada Gairdner International Award for pioneering Research and discovery of medicines for Cystic Fibrosis.

Biz Owner Daily
Apr 7th, 2025
EU Approves Expanded Label for Vertex Pharmaceuticals' Cystic Fibrosis Treatment

Vertex Pharmaceuticals has received approval from the European Union to broaden the label for its cystic fibrosis treatment.

Slater Sentinel
Mar 23rd, 2025
Stevens Capital Management LP Makes New $829,000 Investment in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Stevens Capital Management LP makes new $829,000 investment in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX).

Investing.com
Mar 20th, 2025
BMO maintains Vertex stock Market Perform rating and $41 target

The reaffirmation of the rating and target came after Vertex held its first analyst day since its initial public offering in 2020.